Hepatic Artery Infusional Chemotherapy for Colorectal Liver Metastases

  • Aaron R. Sasson
  • James C. Watson
  • Elin R. Sigurdson
Part of the Cancer Treatment and Research book series (CTAR, volume 109)


Colorectal cancer is diagnosed in 130,000 patients annually, and is the second leading cause of cancer related deaths (1). A significant percentage of patients with colorectal cancer will develop metastases, and the liver is the predominant site in nearly 60% of patients. Of these patients, one quarter will have disease isolated to the liver and only a minority of patients will be candidates for surgical resection. Even with complete tumor removal the five-year survival is less than 40% and recurrences are common (2,3). Administration of systemic chemotherapy for metastatic colorectal cancer provides a response rate less than 30%, and results ;n a median survival only 12 months.


Liver Metastasis Hepatic Artery Colorectal Liver Metastasis Common Hepatic Artery Hepatic Arterial Infusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50(1):7.PubMedCrossRefGoogle Scholar
  2. 2.
    Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: A proposal of a prognostic scoring system. J Am Coll Surg 1999;189:291.PubMedCrossRefGoogle Scholar
  3. 3.
    Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1001 consecutive cases. Ann Surg 1999;230:309.PubMedCrossRefGoogle Scholar
  4. 4.
    Blackshear PJ, Dorman FD, Blackshear PJ Jr, et al. The design and initial testing of an implantable infusion pump. Surg Gynecol Obstet 1972;134:51.PubMedGoogle Scholar
  5. 5.
    Ackerman NB. The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 1974;75:589.PubMedGoogle Scholar
  6. 6.
    Breedis C, Young C. The blood supply of neoplasms in the liver. Am J Pathol 1954;30: 969.PubMedGoogle Scholar
  7. 7.
    Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987;5:1936.Google Scholar
  8. 8.
    Daly JM, Kemeny N, Sigurdson E, Oderman P, Thom A. Regional infusion for colorectal hepatic metastases: A randomized trial comparing the hepatic artery with the portal vein. Arch Surg 1987;122:1273.PubMedCrossRefGoogle Scholar
  9. 9.
    Ensminger WD, Rosowsky A, Raso V. A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784.PubMedGoogle Scholar
  10. 10.
    Weiss L, Grundmann E, Torhorst J, et al. Hematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 1986;150:195.PubMedCrossRefGoogle Scholar
  11. 11.
    Weiss L. Metastatic inefficiency and regional therapy for liver metastases from colorectal carcinoma. Reg Cancer Treat 1989;2:77.Google Scholar
  12. 12.
    Daly J, Kemeny N. The therapy of colorectal hepatic metastases. In: DeVita VT, Hellman S, Rosenberg S (eds.), Important Advances in Oncology. J.B. Lippincott, New York 1986;251.Google Scholar
  13. 13.
    Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 1992:10:896.Google Scholar
  14. 14.
    Balch CM, Urist MM, Soong SJ, McGregor M. A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 1983;198:567.PubMedCrossRefGoogle Scholar
  15. 15.
    Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984;53:1336.PubMedCrossRefGoogle Scholar
  16. 16.
    Weiss GR, Garnick MB, Osteen RT, et al. Long-term arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1983;1:337.PubMedGoogle Scholar
  17. 17.
    Allen-Mersh TG, Earkam S, Fordy C, Abrams K, Houghton J: Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet 1994;344:1255.PubMedCrossRefGoogle Scholar
  18. 18.
    Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989;7:1646.PubMedGoogle Scholar
  19. 19.
    Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma — A randomized trial. Ann Int Med 1987;107:459.PubMedGoogle Scholar
  20. 20.
    Chang AE, Schneider PD, Sugerbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987;206:685.PubMedCrossRefGoogle Scholar
  21. 21.
    Martin JK Jr, O’Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer: a randomized trial. Arch Surg 1990;125:1022.PubMedCrossRefGoogle Scholar
  22. 22.
    Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: longterm results of a prospective randomized trial. J Clin Oncol 1992;10:1112.PubMedGoogle Scholar
  23. 23.
    Lorenz M, Muller HH. Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000;2:243.Google Scholar
  24. 24.
    Kemeny N, Daly J, Oderman P, Niedzwiecki D, Shurgot B. Prognostic variables in patients with hepatic metastases from colorectal cancer: Importance of mnedical assessment of liver involvement. Cancer 1989;63:742.PubMedCrossRefGoogle Scholar
  25. 25.
    Kemeny N, Braun DW. Prognostic factors in advanced colorectal carcinoma:The importance of lactic dehydrogenase, performance status, and white blood cell count. Am JMed 1983;74:786.Google Scholar
  26. 26.
    Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252.Google Scholar
  27. 27.
    Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639.PubMedCrossRefGoogle Scholar
  28. 28.
    Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases J Clin Oncol 1997;15 : 938.PubMedGoogle Scholar
  29. 29.
    Curley SA, Roh MS, Chase JL, Hohn DC. Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases. Am JSurg 1993;166:743.CrossRefGoogle Scholar
  30. 30.
    Moriya Y, Sugihara K, Hojo K, Makuuchi M. Adjuvant hepatic intra-arterial chemotherapy after potentially curative hepatectomy for liver metastases from colorectal cancer: A pilot study. Eur J Surg Oncol 1991;17:519.PubMedGoogle Scholar
  31. 31.
    Kemeny N, Conti JA, Sigurdson E, et al. A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. A potentialGoogle Scholar
  32. 32.
    Kokudo N, Seki M, Ohta H, et al. Effects of systemic and regional chemotherapy after hepatic resection for colorectal metastases. Ann Surg Oncol 1998;5:706.PubMedCrossRefGoogle Scholar
  33. 33.
    Wagman LD, Kemeny MM, Leong L, et al. A prospective randomized evaluation of the treatment of colorectal cancer metastatic to the liver. J Clin Oncol 1990;8:1885.PubMedGoogle Scholar
  34. 34.
    Kemeny MM, Goldberg D, Beatty JD, et al. Results of a prospective randomized trials of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 1986;57: 492.PubMedCrossRefGoogle Scholar
  35. 35.
    Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl JMed 1999;341:2039.Google Scholar
  36. 36.
    Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases. Ann Surg 1998;228:756.PubMedCrossRefGoogle Scholar
  37. 37.
    Kemeny MM, Adak S, Lipsitz S, Gray B, MacDonald J, Benson III AB. Results of the intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous cepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases. Proc Am Soc Clin Oncol 1999;18:1012. (abstract)Google Scholar
  38. 38.
    Hiatt JR; Gabbay J; Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg 1994;220:50.PubMedCrossRefGoogle Scholar
  39. 39.
    Curley SA, Chase JL, Roh MS, Hohn DC. Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 1993;114:928.PubMedGoogle Scholar
  40. 40.
    Daly J, Kemeny N, Oderman P, Botet J. Long-term hepatic arterial infusion chemotherapy. Arch Surg 1984;119:936.PubMedCrossRefGoogle Scholar
  41. 41.
    Kemeny M, Battifora H, Blayney D, et al. Sclerosing cholangitis after continuous hepatic artery infusion of FUDR. Ann Surg 1985;202:176.PubMedCrossRefGoogle Scholar
  42. 42.
    Cohen AM, Higgins J, Waltman AC. Effect of ligation of variant hepatic arterial structures on the completeness of regional chemotherapy infusion. Am JSurg 1987;153:378.CrossRefGoogle Scholar
  43. 43.
    Kaplan WD, D’Orsi CJ, Ensminger WD, Smith EH, Levin DC. Intra-arterial radionuclide infusion: a new technique to assess chemotherapy perfusion patterns. Cancer Treat Rep 1978;62:699.PubMedGoogle Scholar
  44. 44.
    Campbell KA, Burns RC, Sitzmann JV, Lipsett PA, Grochow LB, Niederhuber JE. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol 1993;11:822.PubMedGoogle Scholar
  45. 45.
    Kemeny N, Daly J, Oderman P, et al. Hepatic artery pump infusion toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 1984;2:595.PubMedGoogle Scholar
  46. 46.
    Pettavel J, Gardiol D, Bergier N, et al. Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine. Reg Cancer Treat 1988;1:83.Google Scholar
  47. 47.
    Northover JM, Terblanche J. A new look at the arterial supply of the bile duct in man and its surgical implications. Br J Surg 1979;66:379.PubMedCrossRefGoogle Scholar
  48. 48.
    Doria MI Jr, Shepard KV, Levin B, et al. Liver pathology following hepatic arterial infusion chemotherapy. Cancer 1986;58:855.PubMedCrossRefGoogle Scholar
  49. 49.
    Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer 1992;69:327.PubMedCrossRefGoogle Scholar
  50. 50.
    Hrushesky W, von Roemelling R, Lanning R, Rabatini J. Circadian-shaped infusions of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 1990;8:1504.PubMedGoogle Scholar
  51. 51.
    Davidson BS, Izzo F, Chase JL, et al. Alternating floxuridine and 5-fluorouracil hepatic arterial chemotherapy for colorectal liver metastases minimizes biliary toxicity. Am J Surg 1996;172:244.PubMedCrossRefGoogle Scholar
  52. 52.
    Stagg R, Venook A, Chase J, et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83 :423.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2001

Authors and Affiliations

  • Aaron R. Sasson
    • 1
  • James C. Watson
    • 1
  • Elin R. Sigurdson
    • 1
  1. 1.Fox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations